# Expanding Liver Transplant Immunosuppression Minimization Via Everolimus

> **NCT06280950** · PHASE2 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 340 (estimated)

## Conditions studied

- Liver Transplant

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Tacrolimus (continued reduction)
- **DRUG:** Tacrolimus (maintain 50% reduction)
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT06280950
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-12
- **Primary completion:** 2028-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06280950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06280950, "Expanding Liver Transplant Immunosuppression Minimization Via Everolimus". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT06280950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*